| Bioactivity | N6-(4-Methoxybenzyl)-2’-C-methyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. |
| Name | N6-(4-Methoxybenzyl)-2’-C-methyl adenosine |
| CAS | 2305415-98-7 |
| Formula | C19H23N5O5 |
| Molar Mass | 401.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Man S, et al. Potential and promising anticancer drugs from adenosine and its analogs. Drug Discov Today. 2021 Jun;26(6):1490-1500. [2]. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. |
N6-(4-Methoxybenzyl)-2’-C-methyl adenosine
CAS: 2305415-98-7 F: C19H23N5O5 W: 401.42
N6-(4-Methoxybenzyl)-2’-C-methyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumo
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.